Correlation Between TSH Receptor Antibody Assays and Clinical Manifestations of Graves' Orbitopathy

Overview

Journal Yonsei Med J

Specialty General Medicine

Date 2013 May 28

PMID 23709442

Citations 14

Authors

Sun Young Jang

Dong Yeob Shin

Eun Jig Lee

Young Joon Choi

Sang Yeul Lee

Jin Sook Yoon

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate an association between the levels of serum thyroid-stimulating hormone (TSH)-receptor autoantibodies (TRAbs) and Graves' orbitopathy (GO) activity/severity scores, and compare the performance of three different TRAb assays in assessing the clinical manifestations of GO.

Materials And Methods: Cross-sectional study. Medical records of 155 patients diagnosed with GO between January 2008 and December 2010 were reviewed. GO activity was assessed by clinical activity score (CAS) and severity graded with the modified NOSPECS score by a single observer. Serum TRAb was measured by three different methods: 1st generation thyrotropin-binding inhibitor immunoglobulin (TBII) assay (TRAb1st); 3rd generation TBII assay (TRAb3rd); and biological quantitative assay of thyroid-stimulating immunoglobulin (TSI) using Mc4-CHO cells (Mc4-CHO TSI assay). Results were correlated with scores of activity/severity of thyroid eye disease.

Results: All three assays (TRAb1st, TRAb3rd, and Mc4-CHO TSI) yielded results that were significantly positively correlated with CAS (β=0.21, 0.21, and 0.46, respectively; p<0.05) and proptosis (β=0.38, 0.34, and 0.33, respectively; p<0.05). Mc4-CHO TSI bioassay results were significantly positively correlated with all GO severity indices (soft tissue involvement, proptosis, extraocular muscle involvement, and total eye score; β=0.31, 0.33, 0.25, and 0.39, respectively; p<0.05).

Conclusion: Mc4-CHO TSI bioassay was superior over the two TBIIs in assessing active inflammation and muscle restriction due to GO, whereas TBII assay would be sufficient for evaluation of patients with proptosis.

Citing Articles

Correlation between extraocular muscle enlargement and thyroid autoantibodies in thyroid eye disease.

Koizumi T, Tanaka T, Umeda K, Komiyama D, Obata H Jpn J Ophthalmol. 2024; 68(3):250-258.

PMID: 38609717 PMC: 11087308. DOI: 10.1007/s10384-024-01061-7.

Thyroid stimulating immunoglobulin concentration is associated with disease activity and predicts response to treatment with intravenous methylprednisolone in patients with Graves' orbitopathy.

Hotte G, Kolijn P, de Bie M, de Keizer R, Medici M, van der Weerd K Front Endocrinol (Lausanne). 2024; 15:1340415.

PMID: 38577576 PMC: 10993908. DOI: 10.3389/fendo.2024.1340415.

The changing landscape of thyroid eye disease: current clinical advances and future outlook.

Moledina M, Damato E, Lee V Eye (Lond). 2024; 38(8):1425-1437.

PMID: 38374366 PMC: 11126416. DOI: 10.1038/s41433-024-02967-9.

Comparison of two different TSH-receptor antibody assays: A clinical practice study.

van Balkum M, Schreurs M, Visser W, Peeters R, Dik W Heliyon. 2023; 9(12):e22468.

PMID: 38107298 PMC: 10724564. DOI: 10.1016/j.heliyon.2023.e22468.

HbA1c: an independent risk factor for dysthyroid optic neuropathy.

Wang X, Ye H, Chen R, Yang S, Zhang T, Xiao W Front Endocrinol (Lausanne). 2023; 14:1251209.

PMID: 37881496 PMC: 10597662. DOI: 10.3389/fendo.2023.1251209.

References

Eckstein A, Losch C, Glowacka D, Schott M, Mann K, Esser J . Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy. Br J Ophthalmol. 2009; 93(8):1052-6. DOI: 10.1136/bjo.2007.137265. View

Kamijo K, Murayama H, Uzu T, Togashi K, Kahaly G . A novel bioreporter assay for thyrotropin receptor antibodies using a chimeric thyrotropin receptor (mc4) is more useful in differentiation of Graves' disease from painless thyroiditis than conventional thyrotropin-stimulating antibody assay using.... Thyroid. 2010; 20(8):851-6. DOI: 10.1089/thy.2010.0059. View

Noh J, Hamada N, Inoue Y, Abe Y, Ito K . Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease. Thyroid. 2000; 10(9):809-13. DOI: 10.1089/thy.2000.10.809. View

Kamijo K, Ishikawa K, Tanaka M . Clinical evaluation of 3rd generation assay for thyrotropin receptor antibodies: the M22-biotin-based ELISA initiated by Smith. Endocr J. 2005; 52(5):525-9. DOI: 10.1507/endocrj.52.525. View

Lytton S, Ponto K, Kanitz M, Matheis N, Kohn L, Kahaly G . A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy. J Clin Endocrinol Metab. 2010; 95(5):2123-31. DOI: 10.1210/jc.2009-2470. View

Dragan L, Seiff S, Lee D . Longitudinal correlation of thyroid-stimulating immunoglobulin with clinical activity of disease in thyroid-associated orbitopathy. Ophthalmic Plast Reconstr Surg. 2006; 22(1):13-9. DOI: 10.1097/01.iop.0000192649.23508.f7. View

Goh S, Ho S, Seah L, Fong K, Khoo D . Thyroid autoantibody profiles in ophthalmic dominant and thyroid dominant Graves' disease differ and suggest ophthalmopathy is a multiantigenic disease. Clin Endocrinol (Oxf). 2004; 60(5):600-7. DOI: 10.1111/j.1365-2265.2004.02033.x. View

Massart C, Sapin R, Gibassier J, Agin A, dHerbomez M . Intermethod variability in TSH-receptor antibody measurement: implication for the diagnosis of Graves disease and for the follow-up of Graves ophthalmopathy. Clin Chem. 2008; 55(1):183-6. DOI: 10.1373/clinchem.2008.115162. View

Ponto K, Kanitz M, Olivo P, Pitz S, Pfeiffer N, Kahaly G . Clinical relevance of thyroid-stimulating immunoglobulins in graves' ophthalmopathy. Ophthalmology. 2011; 118(11):2279-85. DOI: 10.1016/j.ophtha.2011.03.030. View

10.

Regensburg N, Wiersinga W, Berendschot T, Potgieser P, Mourits M . Do subtypes of graves' orbitopathy exist?. Ophthalmology. 2010; 118(1):191-6. DOI: 10.1016/j.ophtha.2010.04.004. View

11.

Saravanan P, Dayan C . Thyroid autoantibodies. Endocrinol Metab Clin North Am. 2001; 30(2):315-37, viii. DOI: 10.1016/s0889-8529(05)70189-4. View

12.

Lytton S, Kahaly G . Bioassays for TSH-receptor autoantibodies: an update. Autoimmun Rev. 2010; 10(2):116-22. DOI: 10.1016/j.autrev.2010.08.018. View

13.

Costagliola S, Morgenthaler N, Hoermann R, Badenhoop K, Struck J, Freitag D . Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. J Clin Endocrinol Metab. 1999; 84(1):90-7. DOI: 10.1210/jcem.84.1.5415. View

14.

Peyster R, GINSBERG F, Silber J, Adler L . Exophthalmos caused by excessive fat: CT volumetric analysis and differential diagnosis. AJR Am J Roentgenol. 1986; 146(3):459-64. DOI: 10.2214/ajr.146.3.459. View

15.

Lytton S, Li Y, Olivo P, Kohn L, Kahaly G . Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins. Clin Exp Immunol. 2010; 162(3):438-46. PMC: 3026547. DOI: 10.1111/j.1365-2249.2010.04266.x. View

16.

Michalek K, Morshed S, Latif R, Davies T . TSH receptor autoantibodies. Autoimmun Rev. 2009; 9(2):113-6. PMC: 3753030. DOI: 10.1016/j.autrev.2009.03.012. View

17.

Gerding M, van der Meer J, Broenink M, Bakker O, Wiersinga W, Prummel M . Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf). 2000; 52(3):267-71. DOI: 10.1046/j.1365-2265.2000.00959.x. View

18.

Kamath C, Adlan M, Premawardhana L . The role of thyrotrophin receptor antibody assays in graves' disease. J Thyroid Res. 2012; 2012:525936. PMC: 3345237. DOI: 10.1155/2012/525936. View

19.

Vos X, Smit N, Endert E, Tijssen J, Wiersinga W . Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: a prospective study. Clin Endocrinol (Oxf). 2008; 69(2):311-7. DOI: 10.1111/j.1365-2265.2008.03192.x. View

20.

Eckstein A, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S . Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006; 91(9):3464-70. DOI: 10.1210/jc.2005-2813. View